[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576183":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":25,"responsibleParty":121,"collaborators":11,"id":123,"slug":124,"hasResults":125,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":11,"eligibilityCriteria":129,"healthyVolunteers":125,"sex":130,"minAge":131,"maxAge":11,"enrollmentInfo":132,"targetDuration":11,"studyType":135,"phases":136,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},{"fullName":5,"class":6},"Innate Pharma","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IPH4502 Monotherapy","EXPERIMENTAL",null,[13],"Drug: IPH4502",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","IPH4502","Part 1 (dose escalation) and Part 2 (dose optimization)",[9],[21],{"name":5,"role":22,"phone":23,"phoneExt":11,"email":24},"CONTACT","+33430303030","clinical.trials@innate-pharma.fr",[26,44,57,69,82,95,109],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Massachusetts General Hospital - Boston","RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-71.05977,42.35843,{"lat":38,"lon":37},[41],{"name":42,"role":43,"phone":11,"phoneExt":11,"email":11},"Leon Pappas, MD","PRINCIPAL_INVESTIGATOR",{"facility":45,"status":28,"city":46,"state":47,"zip":48,"country":32,"countryCode":33,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"John Theurer Cancer Center","Hackensack","New Jersey","07601",{"type":35,"coordinates":50},[51,52],-74.04347,40.88593,{"lat":52,"lon":51},[55],{"name":56,"role":43,"phone":11,"phoneExt":11,"email":11},"Martin Gutierrez, MD",{"facility":58,"status":28,"city":59,"state":59,"zip":60,"country":32,"countryCode":33,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Mount Sinai Tisch Cancer Center","New York","10029",{"type":35,"coordinates":62},[63,64],-74.00597,40.71427,{"lat":64,"lon":63},[67],{"name":68,"role":43,"phone":11,"phoneExt":11,"email":11},"Thomas Marron, MD",{"facility":70,"status":28,"city":71,"state":72,"zip":73,"country":32,"countryCode":33,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"NEXT Oncology - Dallas","Dallas","Texas","75039",{"type":35,"coordinates":75},[76,77],-96.80667,32.78306,{"lat":77,"lon":76},[80],{"name":81,"role":22,"phone":11,"phoneExt":11,"email":11},"Shiraj Sen, MD",{"facility":83,"status":28,"city":84,"state":85,"zip":86,"country":32,"countryCode":33,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"NEXT Oncology - Virginia","Fairfax","Virginia","22031",{"type":35,"coordinates":88},[89,90],-77.30637,38.84622,{"lat":90,"lon":89},[93],{"name":94,"role":22,"phone":11,"phoneExt":11,"email":11},"Alex Spira, MD",{"facility":96,"status":28,"city":97,"state":11,"zip":98,"country":99,"countryCode":100,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Centre Léon Bérard","Lyon","69008","France","FR",{"type":35,"coordinates":102},[103,104],4.84789,45.74906,{"lat":104,"lon":103},[107],{"name":108,"role":43,"phone":11,"phoneExt":11,"email":11},"Armelle Vinceneux, MD",{"facility":110,"status":28,"city":111,"state":11,"zip":112,"country":99,"countryCode":100,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Gustave Roussy Cancer Institute","Villejuif","94805",{"type":35,"coordinates":114},[115,116],2.35992,48.7939,{"lat":116,"lon":115},[119],{"name":120,"role":43,"phone":11,"phoneExt":11,"email":11},"Yohann Loriot, MD",{"type":122,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100576183","phase-1-safety-and-tolerability-of-iph4502-in-patients-with-advanced-solid-tumors-100576183",false,"NCT06781983","Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors","A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors","Main Inclusion Criteria:\n\n* Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4\n* Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is available.\n* Measurable disease according to RECIST 1.1.\n* Archival tumor tissue obtained within 4 months of screening and since the last anticancer therapy prior to the study or agree to undergo a tumor biopsy at baseline.\n* Adequate organ function and hematological function.\n\nMain Exclusion Criteria:\n\n* Known or suspected brain metastases.\n* Participants with an active infection, Any other infection requiring systemic treatment or latent infection.\n* Participants with clinically significant comorbidity(s).\n* History of treatment for, or suspicion or confirmed interstitial lung disease (ILD) at baseline.\n* Condition being treated with systemic corticosteroids or immunosuppressive therapy during IPH4502 treatment.\n* Thromboembolic event requiring anticoagulation therapy ≤14 days prior to the first dose of IPH4502.\n* Clinically significant cardiovascular disease and\u002For cardiac repolarization abnormality.\n* Participants with symptomatic heart failure, Acute coronary syndromes\n* Participant is receiving or has received anticancer therapy prior to enrolment that may have impact on the assessment of IPH4502.\n* Major surgery ≤28 days and minor surgery ≤7 days prior to first dose of IPH4502 or 6 months for coronary artery bypass surgery.\n* Concomitant medications or vaccines : Live-attenuated vaccines ≤ 6 weeks prior to first dose of IPH4502; systemic corticosteroids or other immunosuppressive agents within 14 days prior to the first dose of IPH4502; systemic use of moderate or strong CYP 3A4 inhibitors; systemic use of moderate or strong CYP 3A4 inducers.","ALL","18 Years",{"count":133,"type":134},145,"ESTIMATED","INTERVENTIONAL",[137],"PHASE1","This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4",[140],"Advanced or Metastatic Solid Tumors",[142,143,144,145,146,147,148,149,150,151,152,153,154,155,156],"Exatecan","Topo-Isomerase I inhibitor","Squamous cell carcinoma of the head and neck","Esophageal squamous cell carcinoma","Triple negative breast cancer","Non-small cell lung cancer","Gastro-esophageal junction and gastric cancer","Colorectal carcinoma","Ovarian carcinoma","Prostate cancer","Cervical cancer","Melanoma","Urothelial carcinoma","Antibody-drug conjugates","ADC","2026-01-05",{"date":159,"type":160},"2026-01-07","ACTUAL",{"date":162,"type":160},"2025-01-24",{"date":164,"type":134},"2029-04",{"name":5,"class":6},7]